NEW INDICATIONS

Xpovio Approved for Patients with Relapsed or Refractory Multiple Myeloma

JHOP - February 2021 Vol 11, No 1 - FDA Updates, Multiple Myeloma

On December 18, 2020, the FDA approved selinexor (Xpovio; Karyopharm Therapeutics) in combination with bortezomib and dexamethasone for the treatment of adults with multiple myeloma after ≥1 previous therapies. The FDA granted this indication an orphan drug designation.

Selinexor was previously approved in combination with dexamethasone for adults with relapsed or refractory multiple myeloma who have received ≥4 previous therapies, and for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after ≥2 lines of systemic therapy.

The FDA approved the new indication based on data from the BOSTON clinical trial, a randomized open-label, multicenter, active comparator–controlled study in patients with relapsed or refractory multiple myeloma who had received between 1 and 3 previous therapies. Patients were randomized in a 1:1 ratio to once-weekly selinexor orally, in combination with once-weekly bortezomib subcutaneously and low-dose dexamethasone twice-weekly (SVd) or to the standard twice-weekly bortezomib plus low-dose dexamethasone (Vd) regimen.

The main end point was progression-free survival (PFS). The estimated median PFS was 13.9 months (95% confidence interval [CI], 11.7-not estimable) in the SVd arm versus 9.5 months (95% CI, 7.6-10.8) in the Vd arm (estimated hazard ratio, 0.70; 95% CI, 0.53-0.93).

The most common (≥20%) adverse reactions reported in the SVd arm were nausea, fatigue, decreased appetite, diarrhea, peripheral neuropathy, upper respiratory tract infection, decreased weight, cataract, and vomiting. Grade 3 or 4 laboratory abnormalities (≥10%) were thrombocytopenia, lymphopenia, hypophosphatemia, anemia, hyponatremia, and neutropenia.

Related Items
Yescarta First CAR T-Cell Therapy Approved for Follicular Lymphoma
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Lymphoma
Libtayo Receives 2 New Indications: For Basal-Cell Carcinoma and for NSCLC
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Skin Cancer
Abecma First CAR T-Cell Therapy Approved for Multiple Myeloma
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Multiple Myeloma
FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Multiple Myeloma
Cosela First CDK4/6 Inhibitor FDA Approved to Reduce Chemotherapy-Induced Myelosuppression
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Myelosuppression
FDA Approved Breyanzi, Novel CAR T-Cell Therapy, for Large B-Cell Lymphoma
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Lymphoma
Ukoniq, New Targeted Therapy, FDA Approved for Marginal-Zone and Follicular Lymphoma
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Lymphoma
Vyxeos Now Indicated for Pediatric Patients with AML
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Leukemia, Pediatric Cancer
Lorbrena Now FDA Approved for First-Line Treatment of Metastatic NSCLC
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Lung Cancer
Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Patients with Multiple Myeloma Receiving Lenalidomide, Bortezomib, and Dexamethasone
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Multiple Myeloma
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.